78 results about "Precancerous condition" patented technology

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody 4F6 for HPV16 type E7 protein detection and application. The heavy chain variable region CDR sequences and the light chain variable region CDR sequences of the antibody are SEQ ID NO.1-3 and SEQ ID NO.4-6 respectively, and the antibody can be specifically combined with HPV16 type E7 protein without cross reaction. A double-antibody sandwich ELISA detection system constructed based on the antibody is combined with a biotin-avidin amplification technology, the sensitivity reaches 100 pg / mL, and the antibody is suitable for rapid detection of the HPV16 type E7 protein in a cervical exfoliated cell sample. The invention further provides the HPV16 type E7 recombinant protein which is obtained through prokaryotic expression and has immunocompetence, and the HPV16 type E7 recombinant protein is applied to antibody screening and detection. Compared with nucleic acid detection, the method has a lower false positive rate, can be used for early screening of cervical cancer and precancerous lesions, and has a good application prospect.

The invention discloses a radionuclide labeled molecular probe for detecting collagen structure denaturation and a preparation method and application thereof, and relates to the technical field of biology. The structural general formula of the radionuclide labeled molecular probe disclosed by the invention is as follows: K (chelating agent-nuclide)-K-Linker-CHP, wherein K (chelating agent-nuclide) is a lysine residue labeled by a side chain amino coupling chelating agent and a radionuclide; the Linker is a connection joint; cHP is a collagen hybrid peptide with a polypeptide sequence of (GfO) n or (GPO) n. The probe has excellent definition and signal-to-noise ratio, not only can detect pancreatic ductal adenocarcinoma in a pancreatic cancer model, but also can sensitively detect precancerous lesions (such as pancreatic intraepithelial neoplasia lesions) of the pancreatic ductal adenocarcinoma and pulmonary fibrosis lesions in a bleomycin pulmonary fibrosis model. And the kit has important significance on early detection of pancreatic duct adenocarcinoma and reflection of dynamic change of ECM remodeling.

Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface phosphatidylserine, alone or in combination with other therapies, are provided. The radiolabeled phosphatidylserine targeting agent delivers radiation to cells that externally present phosphatidylserine, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled phosphatidylserine targeting agent itself increases the cell surface expression of phosphatidylserine, leading to a feed-forward mechanism that drives further accumulation of the phosphatidylserine targeting agent at target lesions to enhance its therapeutic effect.

The invention relates to the technical field of biological detection, and discloses a reagent composition and a kit for detecting cervical cancer and precancerous lesions of cervical cancer and application of the reagent composition and the kit. The reagent composition provided by the invention is used for detecting the methylation degree of a specific marker gene, and the detection sensitivity and specificity of cervical cancer and high-grade cervical cancer precancerous lesions are at a relatively high level. When the reagent composition is used for screening cervical cancer and precancerous lesions of HPV positive people, compared with conventional cytological detection, the colposcope referral rate is greatly reduced, meanwhile, the detection times for definite diagnosis of high-grade cervical lesions or cervical cancer are reduced, and the waste of medical resources and the examination burden of patients are reduced.

The invention belongs to the technical field of microorganisms, and particularly relates to combined lactobacillus salivarius and application thereof in female genital tract health. The preservation number of the strain is CCTCC NO: M20231719, and the strain has good bacteriostatic ability and dendritic cell (DC) maturation / activation stimulation ability, has no potential safety problem, can regulate vaginal micro-ecological balance, prevent infection caused by exogenous bacteria, effectively improve tumor immunosuppression microenvironment, and has good application prospects. And the method has very important significance on prevention / treatment of vaginal dysbacteriosis patients, gynecological tumors and precancerous lesions thereof.

The invention relates to methylation markers of colorectal polyp / adenoma and colorectal cancer as well as a screening method and application of the methylation markers, and further relates to a construction method of a three-classification model for simultaneously screening colorectal polyp / adenoma and colorectal cancer. Related methylation markers are screened by adopting a methylation co-immunoprecipitation sequencing technology, and a multi-stage classification model is constructed through a characteristic methylation difference region analysis algorithm, so that classification prediction of normal healthy people, colorectal polyp / adenoma people and colorectal cancer people can be realized, high sensitivity is achieved, precancerous lesions can be found as early as possible, and the clinical application prospect is wide. And a new technical scheme is provided for early screening of colorectal cancer.

The present disclosure provides an establishment and use of index for evaluating malignancy level of tissue microenvironment, which can be used to detect the potential of an individual to develop precancerous lesions and to predict the recurrence of tumors without relying on patient survival data.

The invention discloses a biomarker for accurate typing of esophageal squamous carcinoma lesion and application of the biomarker, and belongs to the technical field of molecular biology, the biomarker is SOX2 protein and KDM4B protein which are co-localized in nuclei, and the biomarker is applied to accurate typing of esophageal squamous carcinoma lesion with a non-diagnostic purpose. The cell proportion and distribution conditions of the SOX2 protein and the KDM4B protein are simultaneously displayed on the same section by adopting a double-label immunofluorescence method, and tests prove that the intranuclear co-localization of the SOX2 and the KDM4B can be used as an early warning mark and is used for identifying high-risk patients or early stages of precancerous lesions or distinguishing tumor patients, so that the missed diagnosis rate is reduced, and the diagnosis time is shortened. Therefore, a reliable basis is provided for accurate typing of esophageal squamous carcinoma lesions.

This invention discloses a wired dual-modal imaging capsule endoscopy system, belonging to the field of medical device technology. The system includes a capsule module, a transmission and control module, a dual-modal imaging module, and a signal analysis module. The capsule module is used to achieve 360° circumferential scanning imaging of the esophageal mucosa. The transmission and control module ensures stable transmission of optical and electrical signals and precise control of capsule movement. The dual-modal imaging module integrates an optical coherence tomography submodule and a photoacoustic imaging submodule to acquire tissue morphology information and microvascular distribution information, respectively. The signal analysis module processes the dual-modal signals. This invention achieves three-dimensional high-resolution integrated imaging of the esophageal mucosa without the need for exogenous labeling agents, significantly improving the detection accuracy of early esophageal cancer and precancerous lesions.

This invention discloses a traditional Chinese medicine composition for treating HPV infection, its preparation, and its uses. The composition comprises the following ingredients in the indicated weight percentages: 10-40 parts of *Hedyotis diffusa*, 10-30 parts of *Smilax glabra*, 10-30 parts of *Hedyotis diffusa*, 10-30 parts of *Paeonia suffruticosa*, 10-40 parts of *Lithospermum erythrorhizon*, 10-30 parts of *Dictamnus dasycarpus*, 10-30 parts of *Radix Paeoniae Rubra*, 10-30 parts of *Cicadae Periostracum*, 10-30 parts of *Astragalus membranaceus*, and 10-30 parts of *Glycyrrhiza uralensis*. It effectively inhibits the replication of human papillomavirus (HPV) nucleic acid, thereby effectively treating cervical HPV infection caused by HPV, as well as infectious skin diseases such as cervical precancerous lesions and condyloma acuminata caused by HPV infection.

The present disclosure relates to a composition comprising a peptide having at least 90% homology to a peptide of SEQ ID No. 1 and at least one anti-cancer agent. It also relates to a process of preparing the composition and a method / use of the peptide alone or in combination with at least one anti-cancer agent in preventing or managing or treating cancer / precancerous condition.

The present invention provides a computer implemented method for the prediction of clinical outcomes in patients with cancer or pre-neoplastic conditions through the integration of genomic evolutionary, genomic and clinical. More specifically, the invention provides systems and algorithms that generate prognostic and predictive models based on the combined analysis of molecular features, inferred evolutionary routes, and clinical parameters, enabling patient risk stratification and individualized outcome estimation.

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

The present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine. In particular, the present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine, which is useful for topical application. The present invention also provides the use of such compositions for medical conditions in the keratinizing and non-keratinizing epithelium / skin, such as the treatment of human papillomavirus (HPV)-related pre-cancerous conditions.

The present invention relates to combination therapies for the treatment of cancer, the therapies comprising a piperazine derivative and a chemotherapeutic agent and / or a targeted therapy agent; methods of making such compounds; pharmaceutical compositions comprising such compounds; and methods of using these compounds, particularly methods for targeted therapy of hyperproliferative disorders, including benign hyperproliferative disorders, cancer, and precancerous conditions.

Single-domain antibodies that specifically bind human papillomavirus (HPV) E6 or E7 oncogenic peptides in complex with human major histocompatibility complex (MHC) proteins are described. The E6-MHC-specific and E7-MHC-specific single-domain antibodies were isolated from dromedary camel (VHH) antibody libraries by panning the library with an E6- or E7-derived peptide in complex with HLA-A*02:01. Use of the single-domain antibodies for the detection and treatment of HPV-associated cancers and pre-cancerous lesions is also described.

This specification discloses methods for identifying stable control loci for use in fluorescence in situ hybridization (FISH) assays, and methods for determining whether copy number changes (e.g., amplification) of a target genomic locus (e.g., a gene, e.g., cyclin E1 (CCNE1)) have occurred in a biological sample (e.g., a non-neoplastic sample, a pre-neoplastic lesion, and / or a tumor). In particular, this disclosure provides an expanded repertoire of genomic loci that can serve as stable controls (e.g., stable control loci) for FISH assays aimed at determining copy number changes of a target genomic locus.

Aspects described herein may include a method of diagnosing cervical cancer and pre-cancer conditions, including: utilizing a computer to extract a numerical value corresponding to an order parameter squared (S2) from image data from at least one image of cervical tissue / cells from a patient, wherein the image data includes at least one region having light regions and dark regions, and wherein S2 includes a numerical value quantifying a degree of order present in the image data, and wherein the extracted numerical value comprises a ratio of an area of the light regions to a total area; comparing the extracted numerical value to one or more predefined diagnosis ranges corresponding to stages of cervical cancer and pre-cancer conditions; and diagnosing the stage of the cervical cancer and pre-cancer conditions if the numerical value of the S2 falls within one of the predefined diagnosis ranges.

The invention discloses a traditional Chinese medicine composition for treating hyperplasia of mammary glands and precancerous lesions, a traditional Chinese medicine preparation and a preparation method of the traditional Chinese medicine composition. Comprising 8-12 parts of vinegar-processed radix bupleuri, 12-18 parts of radix paeoniae alba, 12-18 parts of selfheal, 9.5-14.5 parts of thunberg fritillary bulb, 8-12 parts of vinegar-processed curcuma zedoary, 8-12 parts of radix curcumae, 12-18 parts of bighead atractylodes rhizome, 12-18 parts of poria cocos, 12-18 parts of raw oyster shell, 12-18 parts of hedyotis diffusa, 6.4-9.6 parts of schisandra chinensis, 9.5-14.5 parts of glossy privet fruit, 8-12 parts of vinegar-processed turtle shell, 8-12 parts of astragalus membranaceus and 4.8-7.2 parts of honey-fried licorice root. The traditional Chinese medicine composition has the effects of soothing the liver, strengthening the spleen, reducing phlegm, resolving masses, activating blood and eliminating diseases, and can be used for treating hormone-dependent proliferative diseases such as hyperplasia of mammary glands and atypical hyperplasia Multi-target intervention is achieved, the curative effect is remarkable, side effects are small, and wide market and application prospects are achieved.

The invention discloses a library construction method for non-HPV (human papillomavirus) related cervical tumor and precancerous lesion molecular subtypes thereof based on high-throughput sequencing, which comprises the following steps: ultrasonically breaking genome DNA (deoxyribonucleic acid) of a detected sample to obtain a DNA fragment, modifying the tail end, connecting a joint, and performing purification and pre-amplification reaction, namely performing hybridization reaction on a pre-amplification sequence by using a hybridization capture reagent, according to the method, a hybridization capture reagent is adopted, DNA fragments combined through non-specific capture are enriched and removed, then an amplification reaction is carried out, a library is obtained, next-generation sequencing is carried out, original data are subjected to bioinformatics analysis, variation information is obtained, and the hybridization capture reagent comprises specific primers with the sequences shown as SEQ ID NO: 1-175. According to the present invention, the integration of the non-HPV-related cervical tumor and precancerous lesion molecule detection is achieved, the detection can be completed in one experiment, and the sequencing depth is improved by specifically enriching the target region so as to improve the sensitivity of the non-HPV-related cervical tumor and precancerous lesion molecule detection.

The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.

The invention discloses a traditional Chinese medicine composition for treating intestinal tract diseases, which is prepared from the following traditional Chinese medicines in parts by weight: 8-15 parts of selfheal, 20-40 parts of nacre mother of pearl, 5-10 parts of radix bupleuri, 3-8 parts of fried fructus aurantii, 3-8 parts of rhizoma cyperi, 6-12 parts of inula flower and 5-9 parts of pericarpium citri reticulatae. The traditional Chinese medicine composition can be used for pertinently treating liver and gall stagnated heat, stomach qi reversal type bile reflux gastritis or gastroesophageal reflux disease, has the specific treatment effects of relieving inflammation, inhibiting local tissue angiogenesis and preventing precancerous lesions and / or canceration, and has good clinical significance.

This invention discloses metabolic markers for the early auxiliary diagnosis of colorectal cancer in the field of biomedical technology and their applications. The development and utilization of such metabolic markers will provide technical support for the early auxiliary diagnosis of colorectal cancer. Using a non-targeted metabolomics detection method, this invention screened and verified the application value of 10 colorectal cancer metabolites in differentiating colorectal cancer patients from healthy controls, and the application value of 7 metabolites in differentiating precancerous lesions from healthy controls, which can significantly improve the level of early diagnosis of colorectal cancer.

The invention discloses a mass-eliminating composition for treating gastric precancerous lesions as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition for eliminating mass comprises astragalus membranaceus, dragon's blood, cassia twig, poria cocos, radix paeoniae alba, perilla stem, immature bitter orange, mangnolia officinalis, rhizoma nardostachyos, oldenlandia diffusa, cuttlebone, thunberg fritillary bulb, pseudo-ginseng, rheum officinale, dark plum and honey-fried licorice root. Through the steps of decocting twice, concentrating into thick paste and the like, the mass-eliminating composition disclosed by the invention is prepared into the medicine for treating precancerous lesions of gastric cancer. Clinical experiment results show that the medicine provided by the invention can effectively relieve symptoms such as gastral cavity pain, sour regurgitation and the like of patients with precancerous lesions of gastric cancer, can also remarkably improve the degree of gastric mucosa atrophy, intestinal metaplasia and atypical hyperplasia, is high in safety and low in toxic and side effects, and is comprehensively superior to traditional prescriptions. The invention provides a novel medicine composition for treating precancerous lesions of gastric cancer and preventing gastric cancer, and has outstanding clinical application value and wide application prospect.

The present invention relates to methods of sensitizing a subject having cancer or pre-cancer to treatment with immune checkpoint inhibitors, as well as agents for use in sensitizing a subject to such treatment.

The present invention relates to a compound of formula (I) or a salt thereof, wherein the group R is as defined in the specification; and also to a method for preparing the compound and its use as a photosensitizer in photodynamic therapy. The disubstituted ester porphyrin derivatives of the present invention have high ROS production, high activity, and good biosafety. The preparation method is simple, low-cost, and can obtain the target product in good yield, making it particularly suitable for industrial production. They can be used as highly effective photosensitizers for photodynamic therapy to treat hyperproliferative diseases such as cancer or precancerous lesions, particularly cervical cancer or precancerous lesions, or to treat oral diseases such as periodontitis, gingivitis, dental plaque, and dental caries caused by Gram-negative anaerobic cocci, such as Porphyromonas gingivalis.

This invention discloses a multimodal cervical precancerous lesion region segmentation method based on the Swin Transformer. The invention proposes the MSS-Net neural network to overcome the shortcomings of existing methods, fully utilizing the feature extraction capabilities of the Swin Transformer to achieve multimodal fusion of acetic acid and iodine test images. First, HSIL+ regions in colposcopy images are collected and labeled. Then, a target inspection algorithm is used to extract the cervical region, removing noise from non-cervical regions. Next, the preprocessed acetic acid and iodine solution images are input into the Swin Transformer feature extraction network to obtain multi-level feature maps. After weighted fusion of the feature maps through a multimodal attention module, the data is input into a decoder module, where cascaded upsampling generates the final segmentation result. Finally, the MSS-Net neural network is trained using the Dice coefficient and cross-entropy loss function to obtain the trained model. This invention achieves relatively accurate segmentation of cervical precancerous lesion regions through multimodal data fusion and enhanced feature extraction capabilities.

The invention discloses a colorectal tumor risk prediction model based on a DKK4 gene and application thereof, and a construction method of the prediction model comprises the following steps: (1) determining the DKK4 gene as a candidate target through a differential expression gene screened by a public database; (2) evaluating the expression level and the biological function of DKK4 in colorectal cancer and precancerous lesions and the relevance with a Wnt signal channel by utilizing single gene function analysis and combining with a TCGA database; (3) through LASSO regression analysis, constructing a colorectal cancer risk scoring model by using DKK4 and related genes thereof, and screening candidate genes; and (4) verifying the prediction efficiency of the risk scoring model on the one-year and three-year lifetime of the colorectal cancer patient by using an independent data set, and verifying the expression difference of DKK4 in colorectal adenoma and cancer tissues through immunohistochemistry. The DKK4 can be used as a precancerous lesion specific marker, and the expression level of the DKK4 is in positive correlation with the risk of malignant adenoma transformation. The model can effectively evaluate the colorectal cancer progression risk.

The present invention relates to a method for assessing colorectal cancer or a precancerous condition thereof, said method comprising a) detecting the presence or absence of an antibody to ANPEP (Aminopeptidase N, anti-ANPEP antibody) in a blood, serum or plasma sample from the subject, and assessing colorectal cancer or the precancerous condition thereof based on the presence or absence of an antibody to ANPEP determined in step a). The present invention further relates to computer-implemented methods, databases, devices, kits and uses related thereto.

The present application provides the application of Rabdosia serra extract in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the Rabdosia serra extract includes Rabdosia serra aerial part extract, Rabdosia serra underground part extract, Rabdosia serra total part extract and eluate thereof, etc. The present application also provides the application of compounds in Rabdosia serra in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the compounds in Rabdosia serra are selected from oridonin, rabdosin C, norcantharidin, raxofelone and rabdosiin A. The present application proves that Rabdosia serra extract and the compounds in Rabdosia serra have good activity of reversing precancerous lesions of gastric cancer by constructing a cell model (MC cell model) of atrophic gastritis and precancerous lesions of gastric cancer by stimulating GES-1 cells with MNNG.